Entecavir monohydrate

Category	Hepatitis B Virus (HBV)
CAS	209216-23-9
Description	Entecavir triphosphate is a highly potent inhibitor of wild-type HBV Pol and is 100- to 300-fold more potent than lamivudine triphosphate against 3TC-resistant HBV Pol. It competes with dGTP to be incorporated into viral DNA.

Quotation Now

Product Information

Synonyms	Entecavir (monohydrate); UNII-5968Y6H45M; 5968Y6H45M
IUPAC Name	2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1H-purin-6-one;hydrate
Molecular Weight	295.29
Molecular Formula	C12H15N5O3.H2O
Canonical SMILES	C=C1C(CC(C1CO)O)N2C=NC3=C2NC(=NC3=O)N.O
InChI	InChI=1S/C12H15N5O3.H2O/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20;/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20);1H2/t6-,7-,8-;/m0./s1
InChIKey	YXPVEXCTPGULBZ-WQYNNSOESA-N
Boiling Point	661.4°C at 760 mmHg
Melting Point	31°C
Purity	98%
Density	1.81 g/cm3
Solubility	In Vitro: DMSO: ≥ 32 mg/mL (108.37 mM) H2O: 2.8 mg/mL (9.48 mM; Need ultrasonic and warming)
Appearance	White Powder
Application	Antiviral Agents
Storage	Store at -20°C
Complexity	480
Exact Mass	295.12805404
In Vitro	Entecavir monohydrate (BMS200475 monohydrate; SQ34676 monohydrate) has a EC50 of 3.75 nM against HBV. It is incorporated into the protein primer of HBV and subsequently inhibits the priming step of the reverse transcriptase. The antiviral activity of BMS-200475 is significantly less against the other RNA and DNA viruses. Entecavir monohydrate is more readily phosphorylated to its active metabolites than other deoxyguanosine analogs (penciclovir, ganciclovir, lobucavir, and aciclovir) or lamivudine. The intracellular half-life of entecavir is 15 h.
In Vivo	Daily oral treatment with Entecavir monohydrate at doses ranging from 0.02 to 0.5 mg/kg of body weight for 1 to 3 months effectively reduces the level of woodchuck hepatitis virus (WHV) viremia in chronically infected woodchucks.
PSA	139.28000
Target	EC50: 3.75 nM (anti-HBV, HepG2 cell)
Vapor Pressure	2.15E-18mmHg at 25°C